TY - JOUR T1 - Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study JF - Anticancer Research JO - Anticancer Res SP - 4059 LP - 4066 DO - 10.21873/anticanres.14403 VL - 40 IS - 7 AU - BARTOSZ PULA AU - ELZBIETA ISKIERKA-JAZDZEWSKA AU - MONIKA DLUGOSZ-DANECKA AU - AGNIESZKA SZYMCZYK AU - MAREK HUS AU - AGNIESZKA SZEREMET AU - JOANNA DROZD-SOKOLOWSKA AU - ANNA WASZCZUK-GAJDA AU - JAN M. ZAUCHA AU - JADWIGA HOLOJDA AU - WERONIKA PISZCZEK AU - PAWEL STECKIEWICZ AU - MALGORZATA WOJCIECHOWSKA AU - MICHAL OSOWIECKI AU - WANDA KNOPINSKA-POSLUSZNY AU - MAREK DUDZINSKI AU - DARIA ZAWIRSKA AU - EDYTA SUBOCZ AU - JANUSZ HALKA AU - ANDRZEJ PLUTA AU - RYSZARD WICHARY AU - BEATA KUMIEGA AU - BOZENA K. BUDZISZEWSKA AU - WOJCIECH JURCZAK AU - EWA LECH-MARANDA AU - KRZYSZTOF GIANNOPOULOS AU - TADEUSZ ROBAK AU - KRZYSZTOF JAMROZIAK Y1 - 2020/07/01 UR - http://ar.iiarjournals.org/content/40/7/4059.abstract N2 - Background/Aim: To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and Methods: Clinical data of 171 RR-CLL patients treated with ibrutinib were collected within the observational study of the Polish Adult Leukemia Study Group. Results: Median patient age was 64 years. Patients were pretreated with 3 (1-10) median lines of therapy, while 42 (24.6%) had 17p deletion. The median observation time was 40 months (range=1-59 months), while median ibrutinib monotherapy reached 37.5 months (range=0.4-59.2 months). Response was noted in 132 (77.2%) patients. The estimated 5-year progression-free survival (PFS) and overall survival (OS) rates were 61.1% (95%CI=49.3-70.9%) and 56.8% (95%CI=45.6-66.6%), respectively. At the time of analysis 97 (56.7%) remained under ibrutinib monotherapy. Conclusion: Ibrutinib is clinically effective and tolerable as a monotherapy in real-world RR-CLL patients. ER -